^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    alpha-lactalbumin vaccine

    i
    Other names: breast cancer vaccine, alpha-lactalbumin vaccine, aLA breast cancer vaccine
    Associations

    News

    Trials
    Company:
    Anixa Biosci, Cleveland Clinic
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    6d
    CASE6119: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer (clinicaltrials.gov)
    P1, N=45, Recruiting, George T. Budd | Trial completion date: Mar 2025 --> Nov 2025 | Trial primary completion date: Nov 2024 --> May 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • PRL (Prolactin)
    |
    BRCA1 mutation • HER-2 negative • PALB2 mutation • ER negative • PGR negative
    |
    alpha-lactalbumin vaccine
    6ms
    Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer (clinicaltrials.gov)
    P1, N=45, Recruiting, George T. Budd | Trial completion date: Sep 2024 --> Mar 2025 | Trial primary completion date: May 2024 --> Nov 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • PRL (Prolactin)
    |
    BRCA1 mutation • HER-2 negative • PALB2 mutation • ER negative • PGR negative
    |
    alpha-lactalbumin vaccine
    11ms
    Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer (clinicaltrials.gov)
    P1, N=45, Recruiting, George T. Budd | N=30 --> 45 | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Jun 2023 --> May 2024
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • PRL (Prolactin)
    |
    BRCA1 mutation • HER-2 negative • PALB2 mutation • ER negative • PGR negative
    |
    alpha-lactalbumin vaccine
    over1year
    Phase I trial of alpha-lactalbumin vaccine in high-risk operable triple-negative breast cancer (AACR 2023)
    Dose level 2 appears to be the maximum tolerated dose. Accrual to dose levels 1 and 2 will be expanded to further define toxicity and immunologic effects. Accrual of patients with BRCA1 or PALB2 mutations planning to undergo prophylactic mastectomy is beginning in order to define the toxicity and immunologic effects in this group and to determine whether inflammatory changes from occult lactational foci will be produced.
    P1 data • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • PALB2 (Partner and localizer of BRCA2) • IFNG (Interferon, gamma) • IL17A (Interleukin 17A)
    |
    PALB2 mutation
    |
    alpha-lactalbumin vaccine
    almost2years
    Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, George T. Budd | Trial primary completion date: Dec 2022 --> Jun 2023
    Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • IFNG (Interferon, gamma) • IL17A (Interleukin 17A) • PRL (Prolactin)
    |
    BRCA1 mutation • HER-2 negative • PALB2 mutation • ER negative • PGR negative
    |
    alpha-lactalbumin vaccine
    over2years
    Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, George T. Budd | Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: May 2022 --> Dec 2022
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • IFNG (Interferon, gamma) • IL17A (Interleukin 17A) • PRL (Prolactin)
    |
    HER-2 negative • ER negative • PGR negative
    |
    alpha-lactalbumin vaccine
    3years
    Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, George T. Budd | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • IFNG (Interferon, gamma) • IL17A (Interleukin 17A)
    |
    HER-2 negative • ER negative • PGR negative
    |
    alpha-lactalbumin vaccine
    over3years
    Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, George T. Budd | Trial completion date: Dec 2021 --> Sep 2022 | Initiation date: Mar 2021 --> Jul 2021 | Trial primary completion date: Oct 2021 --> Jul 2022
    Clinical • Trial completion date • Trial initiation date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • IFNG (Interferon, gamma) • IL17A (Interleukin 17A)
    |
    HER-2 negative • ER negative • PGR negative
    |
    alpha-lactalbumin vaccine
    almost4years
    Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, George T. Budd
    Clinical • New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • IFNG (Interferon, gamma) • IL17A (Interleukin 17A)
    |
    HER-2 negative • ER negative • PGR negative
    |
    alpha-lactalbumin vaccine